Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

4 Jun 2020

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

MindMed Launches Project Lucy Focused on LSD Experiential Therapy ForAnxiety Disorders Targeting a Phase 2b psychedelic assisted therapy trial for the treatment of anxiety disorders NewYork, NY, June 4, 2020...

By Microdose

Press Releases

2 Jun 2020

MindMed’s Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSDFor Adult ADHD

MindMed’s Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSDFor Adult ADHD Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics ResearcherDr....

By Microdose

Press Releases

27 May 2020

MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies MindMed Further Expands R&D Collaboration with University Hospital Basel’s Liechti Lab with Plans To Develop Next-Gen Psychedelic Therapies Combining LSD and MDMA...

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.